Currently Enrolling Clinical Studies
Adult Clinical Research Studies
Heart and Vascular Research
CAPACITY-Heart Failure with Preserved Ejection Fraction
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Safety and Efficacy of Different Doses of IW-1973 over 12 weeks in Patients with Heart Failure with Preserved Ejection Fraction. For more information please contact Amy at 309-672-3118. The Principal Investigator for this study is Dr. Adler.
GALACTIC-Heart Failure:
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects with Chronic Heart Failure with Reduced Ejection Fraction. For more information about this study, please contact Dean at 309-672-3194. The Principal Investigator for this study is Dr. Adler.
INvested-Influenza vaccine for heart failure patients:
Influenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated heart failure. For more information about this study please contact Deanna at 309-672-4808. The Principal Investigator for this study is Dr. Adler.
VICTORIA-Heart Failure:
A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral Sgc Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) – VerICiguaT Global Study in Subjects With Heart Failure with Reduced Ejection Fraction (VICTORIA). For more information about this two year study, please contact Dean at 309-672-3194. The Principal Investigator for this study is Dr. Adler.
Pulmonary Research
ANDHI-Asthma
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Safety and Efficacy of Benralizumab 30 mg sc in Patients with Severe Asthma Uncontrolled on Standard of Care Treatment. For more information please contact Virginia at 309-672-3153. The Principal Investigator is Dr. Kashyap.
Rheumatology Research
SURPASS-Ankylosing Spondylitis
A randomized, partially-blinded, active-controlled multicenter study of secukinumab to demonstrate reduction of radiographic progression versus GP2017 (adalimumab biosimilar) at 104 weeks and to assess the long term safety, tolerability and efficacy up to 2 years in patients with active ankylosing spondylitis. For more information about this study please contact Deanna at 309-672-4808. The Principal Investigator for this study is Dr. Hanna.
Pediatric Clinical Research Studies
ADAPT-Inflammatory Bowel Disease:
A Phase 4, Multicenter, Open-label Study of Serum Infliximab Concentrations and Efficacy and Safety of Dose Escalation in Pediatric Patients with Inflammatory Bowel Disease. For more information please contact Dean at 309-672-3194. The Principal Investigator for this study is Dr. Khaled.
LIN-MD-62-Constipation:
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel group, safety and efficacy study of a range of Linaclotide (Linzess) Doses administered orally to children ages 7-17 years, who fulfill Modified Rome 3 Criteria for child/Adolescent functional constipation and Rome 3 Criteria for Child/Adolescent IBS.For more information please contact Dean at 309-672-3194. The Principal Investigator for this study is Dr. Khaled.